Address
Email address
Phone number
Website
https://pharmaestica.eePharmaEstica Manufacturing OÜ - Kaasaegsete ravimivormide tootminePharmaEstica Manufacturing OÜ peamine eesmärk on täistsükliga ravimeid ja bioloogiliselt tõhusate, kvaliteetsete ravimite väljatöötamine ja tootmine.
Name
PharmaEstica Manufacturing OÜ
Registry code
10264929
VAT number
EE100541508
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
19.09.1997 (27)
Financial year
01.01-31.12
Capital
220 100.00 €
Activity
21101 - Manufacture of basic pharmaceutical products 72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Oleg Adamchuk 09.03.1972 (52) | 50% - 110 050.00 EUR | Board member | Direct ownership | |
| Nikita Fedonkin 11.06.1986 (38) | 50% - 110 050.00 EUR | - | Direct ownership | |
| Vadim Zubarev 20.04.1970 (54) | - | Board member | - |
| 2019 20.10.2020 | 2020 07.07.2021 | 2021 12.07.2022 | 2022 28.08.2023 | |
|---|---|---|---|---|
| Total Revenue | 234 658 € | 563 049 € | 772 244 € | 830 528 € |
| Net profit (loss) for the period | 2 505 223 € | -1 752 777 € | -1 372 918 € | -1 623 296 € |
| Profit Margin | 1068% | -311% | -178% | -195% |
| Current Assets | 381 781 € | 637 815 € | 388 629 € | 382 950 € |
| Fixed Assets | 2 845 185 € | 2 644 078 € | 2 533 991 € | 2 317 650 € |
| Total Assets | 3 226 966 € | 3 281 893 € | 2 922 620 € | 2 700 600 € |
| Current Liabilities | 1 243 823 € | 3 029 503 € | 4 043 148 € | 5 444 424 € |
| Non Current Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Share Capital | - | - | - | - |
| Equity | 1 983 143 € | 252 390 € | -1 120 528 € | -2 743 824 € |
| Employees | 30 | 34 | 32 | 27 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 310 931.53 € | 56 533.08 € | 60 038.53 € | 25 |
| 2023 Q4 | 271 860.2 € | 66 124.15 € | 69 115.66 € | 25 |
| 2023 Q3 | 209 988.75 € | 83 783.8 € | 88 169.74 € | 23 |
| 2023 Q2 | 172 463.5 € | 86 062.52 € | 88 651.71 € | 26 |
| 2023 Q1 | 225 674.97 € | 54 363.23 € | 57 733.12 € | 26 |
| 2022 Q4 | 423 663.79 € | 67 364.41 € | 70 020.2 € | 28 |
| 2022 Q3 | 315 566.85 € | 75 013.03 € | 79 033.41 € | 27 |
| 2022 Q2 | 209 958.93 € | 67 254.05 € | 70 031.66 € | 27 |
| 2022 Q1 | 41 100 € | 57 154.37 € | 61 281.43 € | 26 |
| 2021 Q4 | 144 317.88 € | 79 121.33 € | 81 160.79 € | 26 |
| 2021 Q3 | 185 688.26 € | 133 191.05 € | 137 347.13 € | 29 |
| 2021 Q2 | 511 677.1 € | 72 009.56 € | 76 091.15 € | 33 |
| 2021 Q1 | 460 822.35 € | 112 826.38 € | 117 633.63 € | 35 |
| 2020 Q4 | 256 088.82 € | 133 825.57 € | 136 646.48 € | 35 |
| 2020 Q3 | 90 535.26 € | 118 334.07 € | 123 890.25 € | 32 |
| 2020 Q2 | 16 027.45 € | 96 394.35 € | 99 758.22 € | 34 |
| 2020 Q1 | 288 604.7 € | 84 304.79 € | 85 761.94 € | 34 |
